Abstract
Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Current Gene Therapy
Title:The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy
Volume: 15 Issue: 1
Author(s): X.G. Chen and W.T. Godbey
Affiliation:
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Abstract: Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Export Options
About this article
Cite this article as:
Chen X.G. and Godbey W.T., The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127094033
DOI https://dx.doi.org/10.2174/1566523214666141127094033 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9)
Current Pharmaceutical Biotechnology Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Tolerance Induction by Gene Transfer to Lymphocytes
Current Gene Therapy PfRIO-2 Kinase is a Potential Therapeutic Target of Antimalarial Protein Kinase Inhibitors
Current Drug Discovery Technologies New Anti-Cancer Strategies in Testicular Germ Cell Tumors
Recent Patents on Anti-Cancer Drug Discovery Morphological Characterization of Lipid Structured Nanoparticles by Atomic Force Microscopy while Minimizing the Formation of Failed Artefacts
Current Nanomaterials Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery The Emerging Roles of the HERC Ubiquitin Ligases in Cancer
Current Pharmaceutical Design Telomerase and Survivin in Colorectal and Pancreatic Cancer – Biomarkers of Life and Death in the Balance Between Proliferation and Apoptosis
Current Cancer Therapy Reviews Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach
Current Drug Targets The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands
Current Drug Discovery Technologies Microarray Data Analysis to Find Diagnostic Approach and Identify Families of Disease-Altered Genes Based on Rank-Reverse of Gene Expression
Current Bioinformatics Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides
Mini-Reviews in Medicinal Chemistry Standardization of Procedures for the Preparation of <sup>177</sup>Lu- and <sup>90</sup>Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Current Radiopharmaceuticals Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations
Current Pharmacogenomics and Personalized Medicine The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews DNA Demethylating Agents and Chromatin-Remodelling Drugs: Which, How and Why?
Current Drug Metabolism